A compound of formula ID, or a pharmaceutically acceptable salt thereof: wherein Ring H is an optionally substituted 5-6 membered monocyclic aromatic ring optionally having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; or an 8-12 membered bicyclic aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur; or a 10-14 membered tricyclic aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur, J H is halogen, -CN, -NO 2, X J, Q J, or X J -Q J or two J H, groups bound to the same carbon atom, together with the carbon atom to which they are bound, optionally form -C=N-OH, -C -, or Ring HH; Ring HH is a 3-8 membered saturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; optionally substituted with 1-4 occurrences of J HH; J HH is halo, CN, oxo, X J, Q J, or X J -Q J., X J is a C 1 -C 10 aliphatic, wherein up to 4 methylene units of the C 1 -C 10 aliphatic are optionally replaced with -O-, -NH, N(C 1 -C 6 aliphatic), -S-, -C -, -C(=NOH)-, -S -, -S 2 -, P, or P; X J is optionally substituted with 0-6 occurrences of halo, OH, or C 1-4 alkyl; or optionally substituted with 0-1 occurrences of CN; Q J is a 3-7 membered monocyclic saturated, fully unsaturated, partially unsaturated, or aromatic ring optionally having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; or an 8-12 membered saturated, fully unsaturated, partially unsaturated, or aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein each Q J is optionally substituted with 1-6 occurences of halo, oxo, CN, or C 1-6 alkyl, wherein up to 2 methylene units of said C 1-6 alkyl are optionally replaced with -O-, -NH, N(C 1 -C 6 aliphatic), -S-, -C -, -S -, or -S 2 -. wherein Ring H is an optionally substituted 5-6 membered monocyclic aromatic ring optionally having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; or an 8-12 membered bicyclic aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur; or a 10-14 membered tricyclic aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur, J H is halogen, -CN, -NO 2, X J, Q J, or X J -Q J or two J H, groups bound to the same carbon atom, together with the carbon atom to which they are bound, optionally form -C=N-OH, -C -, or Ring HH; Ring HH is a 3-8 membered saturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; optionally substituted with 1-4 occurrences of J HH; J HH is halo, CN, oxo, X J, Q J, or X J -Q J., X J is a C 1 -C 10 aliphatic, wherein up to 4 methylene units of the C 1 -C 10 aliphatic are optionally replaced with -O-, -NH, N(C 1 -C 6 aliphatic), -S-, -C -, -C(=NOH)-, -S -, -S 2 -, P, or P; X J is optionally substituted with 0-6 occurrences of halo, OH, or C 1-4 alkyl; or optionally substituted with 0-1 occurrences of CN; Q J is a 3-7 membered monocyclic saturated, fully unsaturated, partially unsaturated, or aromatic ring optionally having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; or an 8-12 membered saturated, fully unsaturated, partially unsaturated, or aromatic ring optionally having 1-6 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein each Q J is optionally substituted with 1-6 occurences of halo, oxo, CN, or C 1-6 alkyl, wherein up to 2 methylene units of said C 1-6 alkyl are optionally replaced with -O-, -NH, N(C 1 -C 6 aliphatic), -S-, -C -, -S -, or -S 2 -.